NCT01833741

A Study of LUMIGAN® RC in the Clinical Setting

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,137 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Conditions

• Glaucoma, Primary Open Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost 0.01%	Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2013-04-17
• Last updated: 2013-09-26
• Results posted: 2013-09-26

Locations

1 site across 1 country: Canada